To investigate the effects of treatment with Myoinositol (an insulin sensitising drug), on circulating insulin, glucose tolerance, ovulation and serum androgens concentrations in women with the Polycystic Ovary Syndrome (PCOS).
A randomised double blind trial.
Forty two women with PCOS between the ages of 18 and 40.
Women were observed by pelvic, ultrasonography and PCOS was found. 13 of the 42 women were taking some drugs (oral contraceptives, insulin-sensitising agents and others) during two months before the study. After randomisation, 23 women received 4 gr. of Mio-Inositol plus 400 mcg of folic acid (Ino-folic®) and 19 women received 400 mcg folic acid (Fertifol®) alone as placebo. The treatment was made for 12-16 weeks.
Main outcome measures
Seven women had impaired glucose tolerance (plasma glucose concentration >140 mg/dl, <200 mg/dl two hours after oral ingestion of 75 g of dextrose). Four of them was assigned to receive Mio-Inositol (Inofolic®) and three were assigned to receive placebo (Folic acid only). the patients were in the follicular phase of the menstrual cycle (serum progesterone concentration lower than 2.5 ng/ml). On the first day blood pressure, weight, height, waist to hip ratio were measured. In the morning, 8:30, 8:45 and 9:00 am., sex hormone binding globulin and serum steroids were obtained. At 9:00 a.m., 75 g of dextrose were ad- ministered and plasma glucose and insulin were measured after 30, 60, 90, 120 minutes. How to take drugs (Myoinositol or placebo orally once a day) was explained to the patients as well as not to change usual habits both for food, sport and lifestyle. The serum progesterone was measured weekly and if the relevant results were over 8 ng/ml the ovulation was supposed. After 6 weeks of drugs (day 49), women in the follicular phase (serum progesterone concentration < 2.5 ng/ml) repeated all the baseline measurement.
Myoinositol increased insulin sensitivity, improved glucose tolerance and decreased glucose stimulated insulin release. In these patients there was a 66% decrement of serum total testosterone and 73% decrement of serum free testosterone concentrations. In addition there was a decrement in systolic and diastolic blood pressure. Plasma triglycerides and total cholesterol concentration decreased. In women with the PCOS, insulin resistance may be related to a deficiency in Myoinositol containing mediator of insulin action and the administration of the Myoinositol improves insulin sensitivity.
In conclusion, Myoinositol decreases serum androgen concentrations, reduces circulating insulin and improves glucose tolerance and other metabolic values altered associated with insulin resistance in women affected by Polycystic ovary syndrome.
Myoinositol is known as the insulin-sensitising agent for women with PCOS. When insulin levels are balanced, the body is better able to regulate overall reproductive function, including hormone balance, ovarian function, egg quality and the menstrual cycle. Haldane Pharma’s product Revosit helps women who are infertile owing to PCOS or Oxidative Stress. Revosit combines clinically studied ingredients which are natural and safe to help support patients to achieve the following such as improved ovarian function, normalise menstrual cycle and improve the quality of the egg.
Revosit is only available in select clinics in Singapore. Please talk to your Doctor or call Haldane Pharmaceuticals at (65) 63330063 for more info.